nach oben

Current Hypertension Reports

Erschienen in:

01.05.2018 | Preeclampsia (VD Garovic, Section Editor)

The Complement Alternative Pathway and Preeclampsia

verfasst von: Layan Alrahmani, Maria Alice V. Willrich

Erschienen in: Current Hypertension Reports | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Significant and intricate immune adaptations are essential for the establishment and maintenance of normal pregnancy. Preeclampsia is a morbid, potentially life-threatening disease for both mother and neonate that occurs uniquely in pregnancy, at least in part, due to maternal immune maladaptation. We aim to review the literature that focuses on case reports, diagnostic approaches, and treatment strategies for disorders of the complement alternative pathway (CAP) as related to preeclampsia.

Recent Findings

There is evidence of complement dysregulation in preeclampsia and HELLP syndrome, similar to that observed in a few rare types of thrombotic microangiopathies. Complement dysregulation may be identified with functional laboratory testing as well as genetic testing.

Summary

Increased utilization of a standardized diagnostic approach to establish whether persistent and/or severe cases of preeclampsia and HELLP syndrome are complement-mediated may lead to development of future treatment strategies, such as complement-targeted therapy.

•• American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Obstet Gynecol. 2013;122:1122–31. https://doi.org/10.1097/01.AOG.0000437382.03963.88. There are the guidelines for definitions and management of all forms of preeclampsia. CrossRef

Saito S, Shiozaki A, Nakashima A, et al. The role of the immune system in preeclampsia. Mol Asp Med. 2007;28:192–209. https://doi.org/10.1016/j.mam.2007.02.006.CrossRef

Marzi M, Vigano A, Trabattoni D, et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol. 1996;106:127–33.CrossRefPubMedPubMedCentral

Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol. 2001;2:64–8. https://doi.org/10.1038/83183.CrossRefPubMed

Ban Y, Zhao Y, Liu F, Dong B, Kong B, Qu X. Effect of indoleamine 2,3-dioxygenase expressed in HTR-8/SVneo cells on decidual NK cell cytotoxicity. Am J Reprod Immunol. 2016;75:519–28. https://doi.org/10.1111/aji.12481.CrossRefPubMed

Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, et al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med. 2005;17:239–45. https://doi.org/10.1080/14767050500072722.CrossRefPubMedPubMedCentral

Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–97. https://doi.org/10.1038/ni.1923.CrossRefPubMedPubMedCentral

Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MAV (2016) Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation. pp 1–75.

Botto M, Kirschfink M, Macor P, Pickering MC, Würzner R, Tedesco F. Complement in human diseases: lessons from complement deficiencies. Mol Immunol. 2009;46:2774–83. https://doi.org/10.1016/j.molimm.2009.04.029.CrossRefPubMed

10.

•• Hoffman MC, Rumer KK, Kramer A, Lynch AM, Winn VD. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol. 2014;71:55–60. https://doi.org/10.1111/aji.12162. Cross-section study in preeclampsia with severe features versus normal controls. Complement factor B activation fragment Bb (specific for complement alternative pathway) in bmaternal and umbilical venous blood appears to be increased in preeclamptics when compared to controls. CrossRefPubMed

11.

•• Sones JL, Merriam AA, Seffens A, et al (2017) Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia. FASEB J fj.201701008R. doi: https://doi.org/10.1096/fj.201701008R. An animal study on gravid mice revealed complement gene up-regulation in high blood pressure mice compared to controls. Altered expression of VEGF pathway genes in high blood pressure mice implantation sites preceded complement dysregulation.

12.

Einarsson JI, Sangi-Haghpeykar H, Gardner MO. Sperm exposure and development of preeclampsia. Am J Obstet Gynecol. 2003;188:1241–3.CrossRefPubMed

13.

Robillard PY, Hulsey TC, Périanin J, et al. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet (London, England). 1994;344:973–5.CrossRef

14.

Koelman CA, Coumans AB, Nijman HW, et al. Correlation between oral sex and a low incidence of preeclampsia: a role for soluble HLA in seminal fluid? J Reprod Immunol. 2000;46:155–66.CrossRefPubMed

15.

• Tsai H-M, Kuo E. From gestational hypertension and preeclampsia to atypical hemolytic uremic syndrome. Obstet Gynecol. 2016;127:907–10. https://doi.org/10.1097/AOG.0000000000001340. A case report in which a patient was misdiagnosed with preeclampsia and HELLP syndrome one pregnancy, TTP in another pregnancy, and was finally given the correct diagnosis for atypical HUS in her third pregnancy, demostrating the great imitators.CrossRefPubMed

16.

Abraham KA, Kennelly M, Dorman AM, Walshe JJ. Pathogenesis of acute renal failure associated with the HELLP syndrome: a case report and review of the literature. Eur J Obstet Gynecol Reprod Biol. 2003;108:99–102.CrossRefPubMed

17.

Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:1035–50. https://doi.org/10.1681/ASN.2004100861.CrossRefPubMed

18.

Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676–87. https://doi.org/10.1056/NEJMra0902814.CrossRefPubMed

19.

Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol. 2007;109:956–66. https://doi.org/10.1097/01.AOG.0000258281.22296.de.CrossRefPubMed

20.

Fakhouri F. Pregnancy-related thrombotic microangiopathies: clues from complement biology. Transfus Apher Sci. 2016;54:199–202. https://doi.org/10.1016/j.transci.2016.04.009.CrossRefPubMed

21.

•• Sabau L, Terriou L, Provot F, Fourrier F, Roumier C, Caron C, et al. Are there any additional mechanisms for haemolysis in HELLP syndrome? Thromb Res. 2016;142:40–3. https://doi.org/10.1016/j.thomres.2016.03.014. Prospective observational study of 16 HELLP patients demonstrated that complement dysregulation is a prominent mechanism in hemolysis in these patients.CrossRefPubMed

22.

• Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. 2013;62:1040–5. https://doi.org/10.1161/HYPERTENSIONAHA.113.01420. Case–control study in which those with preeclampsia had marked elevations in urinary C5b-9. Although complement elevations of complement components were noted, they did not differ preeclampsia from chronic hypertension, supporting the hypothesis that complement markers in urine, rather than plasma, better reflect complement dysregulation.CrossRefPubMed

23.

Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM. Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes. Obstet Gynecol. 2011;117:75–83. https://doi.org/10.1097/AOG.0b013e3181fc3afa.CrossRefPubMedPubMedCentral

24.

Lynch AM, Murphy JR, Byers T, Gibbs RS, Neville MC, Giclas PC, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol. 2008;198:385.e1–9. https://doi.org/10.1016/j.ajog.2007.10.793.CrossRef

25.

• Ma Y, Kong L-R, Ge Q, et al. Complement 5a-mediated trophoblasts dysfunction is involved in the development of pre-eclampsia. J Cell Mol Med. 2017; https://doi.org/10.1111/jcmm.13466. This study demonstrates that complement 5a (C5a) plays a pivotal role in aberrant placentation by detecting elevated C5a deposition in macrophages and C5a receptor expression in trophoblasts of preeclamptic placentas.

26.

•• Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MAV. Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation. Adv Clin Chem. 2016;77:1–75. https://doi.org/10.1016/bs.acc.2016.06.001. The basis of complement testing in common diseases affected by complement dysregulation is described in depth in this article. CrossRefPubMed

27.

• Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15–39. https://doi.org/10.1007/s00467-015-3076-8. An international consensus to approaching the diagnosis and management of atypical HUS in children. Here, HELLP syndrome is classified as as TMA. CrossRefPubMed

28.

• Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, et al. Thrombotic microangiopathy care pathway: a consensus statement for the Mayo Clinic complement alternative pathway-thrombotic microangiopathy (CAP-TMA) disease-oriented group. Mayo Clin Proc. 2016;91:1189–211. https://doi.org/10.1016/j.mayocp.2016.05.015. The Mayo Clinic approach to diagnosis of complement alternative pathway thrombotic microangiopathy disorders is described here, which includes atypical HUS. CrossRefPubMed

29.

• Fakhouri F, Jablonski M, Lepercq J, Blouin J, Benachi A, Hourmant M, et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood. 2008;112:4542–5. https://doi.org/10.1182/blood-2008-03-144691. An early report of genetic variants in complement alternative pathway regulatory proteins in 11 patients with HELLP syndrome. CrossRefPubMed

30.

Crovetto F, Borsa N, Acaia B, Nishimura C, Frees K, Smith RJH, et al. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med. 2012;25:2322–5. https://doi.org/10.3109/14767058.2012.694923.CrossRefPubMed

31.

Józsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111:1512–4. https://doi.org/10.1182/blood-2007-09-109876.CrossRefPubMed

32.

Dragon-Durey M-A, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010;21:2180–7. https://doi.org/10.1681/ASN.2010030315.CrossRefPubMedPubMedCentral

33.

Sellier-Leclerc A-L, Fremeaux-Bacchi V, Dragon-Durey M-A, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392–400. https://doi.org/10.1681/ASN.2006080811.CrossRefPubMed

34.

•• Vaught AJ, Gavriilaki E, Hueppchen N, Blakemore K, Yuan X, Seifert SM, et al. Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome. Exp Hematol. 2016;44:390–8. https://doi.org/10.1016/j.exphem.2016.01.005. A comprehensive study demonstrating alternative complement pathway activation in preeclamptics and those with HELLP syndrome, in addition to demonstrating a significant decrease in cell killing after mizing HELLP serum with eculizumab-containing serum. CrossRefPubMedPubMedCentral

35.

Ardissino G, Wally Ossola M, Baffero GM, et al. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol. 2013;122:487–9. https://doi.org/10.1097/AOG.0b013e31828e2612.CrossRefPubMed

36.

Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373:1032–9. https://doi.org/10.1056/NEJMoa1502950.CrossRefPubMed

37.

Kelly R, Arnold L, Richards S, Hill A, Bomken C, Hanley J, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010;149:446–50. https://doi.org/10.1111/j.1365-2141.2010.08099.x.CrossRefPubMed

38.

Hallstensen RF, Bergseth G, Foss S, Jæger S, Gedde-Dahl T, Holt J, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. 2015;220:452–9. https://doi.org/10.1016/j.imbio.2014.11.003.CrossRefPubMed

39.

•• Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta. 2013;34:201–3. https://doi.org/10.1016/j.placenta.2012.11.014. A report of one case of HELLP syndrome at 26 weeks in which the patient was started on eculizumab and the pregnancy was safely prolonged by approximately 3 weeks. CrossRefPubMed

40.

• McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:734–7. https://doi.org/10.15585/mmwr.mm6627e1. A report by the Center for Disease Control and Prevention demonstrating 16 cases of meningococcal disease in those receiving eculizumab between 2008–2016, despite receipt of the vaccine. CrossRefPubMedPubMedCentral

41.

Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 2014;85:1151–60. https://doi.org/10.1038/ki.2013.373.CrossRefPubMed

42.

Heggermont WA, Verhelst C, De Wilde K, et al. A case of HELLP syndrome: an immuno-“logical” approach. Acta Clin Belg. 67:375–7. https://doi.org/10.2143/ACB.67.5.2062695.

43.

Chou M-M, Chen Y-F, Kung H-F, Liu CK, Sun L, Chen WC, et al. Extensive hepatic infarction in severe preeclampsia as part of the HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): evolution of CT findings and successful treatment with plasma exchange therapy. Taiwan J Obstet Gynecol. 2012;51:418–20. https://doi.org/10.1016/j.tjog.2012.07.018.CrossRefPubMed

44.

Vafaeimanesh J, Nazari A, Hosseinzadeh F. Plasmapheresis: lifesaving treatment in severe cases of HELLP syndrome. Casp J Intern Med. 2014;5:243–7.

45.

Diamante Chiodini B, Davin J-C, Corazza F, Khaldi K, Dahan K, Ismaili K, et al. Eculizumab in anti-factor H antibodies associated with atypical hemolytic uremic syndrome. Pediatrics. 2014;133:e1764–8. https://doi.org/10.1542/peds.2013-1594.CrossRefPubMed

Titel: The Complement Alternative Pathway and Preeclampsia
verfasst von: Layan Alrahmani
Maria Alice V. Willrich
Publikationsdatum: 01.05.2018
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 5/2018
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-018-0836-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

The Role of Circadian Rhythms in the Hypertension of Diabetes Mellitus and the Metabolic Syndrome

Endovascular Baroreflex Amplification for Resistant Hypertension

Modulation of Vascular Reactivity by Perivascular Adipose Tissue (PVAT)

A Systematic Review of Sleep, Hypertension, and Cardiovascular Risk in Children and Adolescents

Correction to: Dimerization of AT2 and Mas Receptors in Control of Blood Pressure